August 22nd 2025
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.
Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer
Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient.
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
March 15th 2017In this article, we review seminal articles that have evaluated the molecular architecture of pancreatic cancer. We compare the methods used and the molecular subtypes defined, and assess the predominant subgroups in order to better understand which therapies may improve patient outcomes.
Incomplete Neoadjuvant Radiation Linked to Worse Outcomes for Rectal Cancer
March 10th 2017Completing a course of preoperative radiotherapy prior to undergoing surgical resection for rectal cancer was associated with improved survival compared with patients who had an incomplete course of radiotherapy.